CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 464 enrolled
Drug / intervention
Aveir DR Leadless Pacemaker Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05252702
NCT05252702N/ACompleted
CompareCT.gov

Aveir Dual-Chamber Leadless i2i IDE Study

Abbott Medical Devices·interventional·Posted Feb 23, 2022·Updated May 27, 2026

In Brief

A clinical study evaluating Aveir DR Leadless Pacemaker System for Cardiac Pacemaker, Artificial and 2 related conditions. Completed, enrolled 464 participants across 78 sites in 13 countries.

Detailed Summary

Prospective, non-randomized, multi-center, international study designed to evaluate the safety and effectiveness of the Aveir™ Dual-Chamber (DR) Leadless Pacemaker system.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiac Pacemaker, Artificial, Cardiac Rhythm Disorder, Bradycardia
CountriesAustria, Belgium, Canada, Czechia, France, Hong Kong, Italy, Japan, Netherlands, Spain, Taiwan, United Kingdom, United States
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedFeb 23, 2022
Enrollment StartFeb 2, 2022
Primary CompletionAug 2, 2023
Study CompletionFeb 3, 2026
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 4.4 years ago

Interventions

Aveir DR Leadless Pacemaker Systemdevice

Patients will undergo a dual chamber leadless pacemaker system implant wherein a leadless pacemaker will be implanted in the right ventricle and right atrium